Adaptimmune Therapeutics (ADAP) Competitors $0.28 0.00 (-0.25%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP vs. CMPX, AVIR, TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, and DRUGShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Bright Minds Biosciences Adaptimmune Therapeutics (NASDAQ:ADAP) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership. Does the MarketBeat Community favor ADAP or CMPX? Adaptimmune Therapeutics received 280 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 81.03% of users gave Compass Therapeutics an outperform vote while only 63.50% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes32763.50% Underperform Votes18836.50% Compass TherapeuticsOutperform Votes4781.03% Underperform Votes1118.97% Which has more volatility and risk, ADAP or CMPX? Adaptimmune Therapeutics has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Which has better earnings and valuation, ADAP or CMPX? Compass Therapeutics has lower revenue, but higher earnings than Adaptimmune Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$178.03M0.40-$113.87M-$0.27-1.03Compass Therapeutics$850K300.16-$42.49M-$0.37-4.99 Do institutionals and insiders believe in ADAP or CMPX? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer ADAP or CMPX? In the previous week, Compass Therapeutics had 5 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 9 mentions for Compass Therapeutics and 4 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 1.37 beat Compass Therapeutics' score of 0.52 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ADAP or CMPX more profitable? Compass Therapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Compass Therapeutics' return on equity of -32.37% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Compass Therapeutics N/A -32.37%-30.67% Do analysts prefer ADAP or CMPX? Adaptimmune Therapeutics currently has a consensus target price of $1.83, indicating a potential upside of 558.27%. Compass Therapeutics has a consensus target price of $13.38, indicating a potential upside of 624.93%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryCompass Therapeutics beats Adaptimmune Therapeutics on 12 of the 19 factors compared between the two stocks. Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.51M$2.96B$5.50B$7.96BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-1.2630.1122.6318.55Price / Sales0.40493.41397.30103.38Price / CashN/A168.6838.1834.62Price / Book1.643.176.704.25Net Income-$113.87M-$72.35M$3.23B$248.27M7 Day Performance4.28%0.66%1.36%1.28%1 Month Performance11.20%7.89%3.85%3.75%1 Year Performance-77.02%-22.87%15.87%5.31% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics3.435 of 5 stars$0.28-0.3%$1.83+563.0%-76.7%$71.51M$178.03M-1.26490Analyst ForecastShort Interest ↓Positive NewsGap DownCMPXCompass Therapeutics3.386 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑Analyst RevisionAVIRAtea Pharmaceuticals3.1648 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870Positive NewsTERNTerns Pharmaceuticals4.2794 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6347 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9782 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100High Trading VolumeATXSAstria Therapeutics2.5439 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageSLRNAcelyrin3.0014 of 5 stars$2.28+3.6%$9.60+321.1%-40.9%$230.07MN/A-0.93135Positive NewsCDTXCidara Therapeutics4.2494 of 5 stars$20.69+6.4%$39.14+89.2%+74.4%$226.62M$1.28M-0.8190Upcoming EarningsAnalyst ForecastNews CoverageHUMAHumacyte2.8057 of 5 stars$1.45-13.7%$13.71+845.8%-63.0%$224.92M$1.57M-1.08150News CoverageDRUGBright Minds Biosciences3.3208 of 5 stars$31.89-3.7%$84.33+164.5%+2,970.0%$224.63MN/A-187.58N/ANews Coverage Related Companies and Tools Related Companies CMPX Alternatives AVIR Alternatives TERN Alternatives ACB Alternatives SLDB Alternatives ATXS Alternatives SLRN Alternatives CDTX Alternatives HUMA Alternatives DRUG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAP Stock Free ADAP Stock Alerts